Yulia Petra Rivelis, MD
Pain Management · Santa Rosa
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
- Since medical school
- 10 years
- Graduated 2016
Offices
2 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Rivelis’s office at (415) 600-1020 to ask if they take your plan before you enroll.
California Medical Board record
Licence A180148 · Current
Licensed to practise in California · since 2022 · expires 2028-07-31 · St. George'S University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Anesthesiology - Pain Medicine
- American Board of Physical Medicine and Rehabilitation - Physical Medicine and Rehabilitation
Original Medicare doctor bills
$60,361
Medicare paid this office $60,361 for 174 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| New patient visit (60+ min) | 106 | $18,624 | $176 |
| Return visit (30+ min) | 77 | $14,126 | $105 |
| Long return visit (40+ min) | 38 | $7,702 | $151 |
| Short return visit (20+ min) | 62 | $6,638 | $71 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 15 | $1,911 | $96 |
See all 10 services
| New patient visit (60+ min) | 106 | $18,624 | $176 |
| Return visit (30+ min) | 77 | $14,126 | $105 |
| Long return visit (40+ min) | 38 | $7,702 | $151 |
| Short return visit (20+ min) | 62 | $6,638 | $71 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 15 | $1,911 | $96 |
| New patient visit (45+ min) | 19 | $1,888 | $99 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 16 | $1,547 | $97 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | 15 | $633 | $42 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 13 | $178 | $14 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 39 | $152 | None |
Procedures year by year
| Procedure | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 22 | 25 | – | 16 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | – | 19 | – | 15 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | – | – | – | 20 |
| Injection of trigger points, 1-2 muscles | – | – | 15 | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
174 Original Medicare patients in 2024. Average age 74 · Under 65 6% · 85 and older 12% · Women 66% · Also on Medicaid 10% · Health risk score 1.21. At or below the middle of the specialty; the typical pain management clinician is at 1.38.
Conditions among them: High blood pressure 66% · Depression 31% · Coronary heart disease 28% · Diabetes 26% · Atrial fibrillation 22% · Chronic kidney disease 21% · Heart failure 14% · Cancer 13% · COPD 13% · Dementia 7%.
The office billed $270,350, Medicare allowed $81,281 and paid $60,361; for 858 services of 29 kinds; $1,413 of it was for drugs given in the office and $58,948 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 174 | 858 | 74 | 1.21 | $270,350 | $60,361 |
| 2023 | 163 | 515 | 74 | 1.08 | $174,965 | $41,311 |
| 2022 | 81 | 676 | 66 | 1.01 | $200,965 | $22,153 |
| 2021 | 26 | 588 | 63 | 1.51 | $154,351 | $10,339 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| New patient visit (60+ min) | 97 | $16,011 | $165 |
| Long return visit (40+ min) | 56 | $11,365 | $150 |
| New patient visit (45+ min) | 31 | $4,005 | $129 |
| Return visit (30+ min) | 38 | $3,827 | $87 |
| Short return visit (20+ min) | 14 | $1,253 | $78 |
| Injection of trigger points, 1-2 muscles | 11 | $694 | $46 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 17 | $75 | None |
2022: 5 services
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 20 | $6,509 | $260 |
| New patient visit (60+ min) | 34 | $6,273 | $185 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | 16 | $2,024 | $107 |
| Injection, dexamethasone sodium phosphate, 1 mg | 25 | $43 | None |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 25 | $6 | $0 |
2021: 3 services
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 19 | $6,370 | $290 |
| Injection, dexamethasone sodium phosphate, 1 mg | 24 | $50 | None |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 24 | $8 | $0 |
Drugs they prescribed that Part D paid
$4,057
Pharmacies billed $4,057 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 7% of their Part D prescriptions (20 of 270) in 2024. At or below the middle of the specialty; the typical pain management clinician is at 44%.
266 generic and fewer than 11 brand-name prescriptions · $4,057 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Gabapentin | 118 | $1,272 | $11 |
| Pregabalin | 31 | $498 | $16 |
| Cyclobenzaprine | 31 | $385 | $12 |
| Tizanidine | 30 | $205 | $7 |
Year by year
| 2024 | 270 | 83 | 7% (20) | None | $4,057 |
| 2023 | 222 | 79 | 9% (20) | None | $6,604 |
| 2022 | 870 | 146 | 41% (356) | 7% | $45,164 |
| 2021 | 740 | 217 | 17% (126) | 3% | $17,581 |
| 2020 | 110 | 54 | None | None | $4,222 |
| 2019 | 69 | 19 | 0% (0) | None | $3,760 |
| 2018 | 39 | 18 | 0% (0) | None | $4,036 |
| 2017 | 85 | 37 | 0% (0) | None | $11,994 |
| 2016 | 36 | 20 | 0% (0) | None | $686 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 5 drugs
| Lidocaine | 18 | $2,330 | $129 |
| Gabapentin | 86 | $1,206 | $14 |
| Tizanidine | 43 | $592 | $14 |
| Pregabalin | 14 | $343 | $25 |
| Cyclobenzaprine | 14 | $108 | $8 |
2022: 16 drugs
| Oxycontin | 20 | $9,836 | $492 |
| Oxycodone | 187 | $7,765 | $42 |
| Diclofenac | 93 | $3,006 | $32 |
| Gabapentin | 143 | $1,863 | $13 |
| Oxycodone-Acetaminophen | 64 | $1,566 | $24 |
| Cyclobenzaprine | 30 | $1,208 | $40 |
| Baclofen | 23 | $1,027 | $45 |
| Tizanidine | 96 | $949 | $10 |
| Morphine Sulfate Er | 15 | $661 | $44 |
| Alprazolam | 48 | $599 | $12 |
| Endocet | 14 | $479 | $34 |
| Hydrocodone-Acetaminophen | 13 | $369 | $28 |
| Zolpidem | 13 | $243 | $19 |
| Pregabalin | 11 | $187 | $17 |
| Tramadol | 18 | $151 | $8 |
| Tramadol Hcl-Acetaminophen | 11 | $146 | $13 |
2021: 13 drugs
| Amitriptyline | 70 | $4,374 | $62 |
| Diclofenac | 71 | $1,836 | $26 |
| Gabapentin | 201 | $1,769 | $9 |
| Oxycodone | 61 | $1,226 | $20 |
| Pregabalin | 25 | $970 | $39 |
| Duloxetine | 37 | $822 | $22 |
| Tizanidine | 65 | $681 | $10 |
| Lidocaine-Prilocaine | 11 | $426 | $39 |
| Oxycodone-Acetaminophen | 22 | $411 | $19 |
| Morphine Sulfate Er | 12 | $208 | $17 |
| Cyclobenzaprine | 23 | $157 | $7 |
| Naproxen | 14 | $117 | $8 |
| Meloxicam | 28 | $35 | $1 |
2020: 3 drugs
| Duloxetine | 13 | $159 | $12 |
| Gabapentin | 15 | $123 | $8 |
| Tizanidine | 17 | $113 | $7 |
2019: 1 drug
| Gabapentin | 15 | $172 | $11 |
Money from drug and device companies
$104 in 2023
| 2023 | 2 | 3 | None | $104 |
| 2022 | 3 | 3 | None | $44 |
| 2021 | 4 | 22 | None | $1,011 |
| 2020 | 4 | 14 | None | $3,945 |
| 2019 | 1 | 1 | None | $127 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Boston Scientific | Wavewriter Alpha Prime 16 | $58 | 2 payments
|
| Abbott Laboratories | Proclaim | $46 | 1 payment
|
See all 3 published payments
| Boston Scientific | Meals · 2023-11-09 | Wavewriter Alpha Prime 16 | $13 |
| Boston Scientific | Meals · 2023-03-16 | None | $45 |
| Abbott Laboratories | Meals · 2023-03-03 | Proclaim | $46 |
See earlier years (2022, 2021, 2020, 2019)
2022: $44
| Abbvie | Botox | $15 | 1 payment
|
| Allergan | Botox | $15 | 1 payment
|
| Bioventus | Gelsyn-3 | $15 | 1 payment
|
2021: $1,011
| Boston Scientific | General - Pain Management | $489 | 11 payments
|
| Nevro | Omnia | $279 | 2 payments
|
| Medtronic | Vectris | $228 | 8 payments
|
| Allergan | Botox | $15 | 1 payment
|
2020: $3,945
| Boston Scientific | Spectra Wavewriter | $2,080 | 8 payments
|
| Medtronic USA | Synchromed | $1,704 | 4 payments
|
| Gilead Sciences | Vemlidy | $125 | 1 payment
|
| Merz North America | Xeomin | $36 | 1 payment
|
2019: $127
| Allergan | Botox | $127 | 1 payment
|
Professional record
- NPI
- 1003269242
- Licence
- CA A180148, PA MT212134California A180148: Current · expires 2028-07-31
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 2081P2900X (2081P2900X); Internal medicine (207R00000X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2016-07-22
- NPI last updated
- 2022-10-26
- NPI record certified
- 2022-10-26
This is when the NPI record was last certified, not a medical board exam.